NEFL and Alzheimer disease: In the CNS, Strickland et al. measured plasma clotting times and bradykinin levels (plasma and CSF) in AD patients directly (Bergamschini et al., 2001), finding that the level of bradykinin increased linearly with the severity of cognitive impairment and the AD biomarkers, neurofilament light chain and Aβ1−42.